Empresa

BIOBank, a French leader in bone allografts, and Spineart are proud to announce a strategic partnership aimed at improving access to high-quality allogenic bone substitutes for spine surgeons in France and Switzerland.

A Synergistic Approach to Spinal Fusion

Under the agreement, Spineart will promote BIOBank’s portfolio, with a focus on BIOBank Synergy® – a moldable natural putty designed for bone fusion – leveraging its well-established commercial spine network, ensuring a wide market coverage in both countries.

Spineart’s fusion products and BIOBank’s biologic solutions complement each other by offering spine surgeons a complete, integrated approach to spinal fusion combining advanced implants with high-quality allografts that support effective bone healing.

Strengthening European Leadership

Already distributing BIOBank products in Spain, Spineart is now expanding its biologics offering to France and Switzerland. As a major player in the French spine market, Spineart is the ideal partner to deliver surgeons the BioBank products.

Alexandre Tepas, CEO, BIOBank said: “We are thrilled to join forces with Spineart. Their proven expertise and extensive network make them the ideal partner to accelerate the adoption of our bone allografts in spine surgery. Together, we will not only expand into key markets, but also support surgeons in their practice and, most importantly, improve outcomes for patients.”

Jerome Trividic, CEO, Spineart added: “We are expanding our European leadership by integrating BIOBank’s allografts, sourced from living donors, into Spineart’s procedural spine surgery offering. This partnership strengthens our ability to provide surgeons with a complete solution for each intervention, combining cutting-edge implants and biologics to support reproducible workflows and deliver optimized patient outcomes.”

About BIOBank

Founded in 1999, BIOBank is a leading French human tissue bank specializing in production allogenic bone grafts for orthopedic, spinal, dental and maxillofacial applications. BIOBank masters its value chain: from the collection from living donors, to the preparation of BIOBank allografts using Supercrit® technology, and their distribution on multiple European markets (Switzerland via its affiliate NEUTROMEDICS, Spain, Poland and the United Kingdom via its partners). BIOBank’s product portfolio includes geometrical shapes, powder, and granules as well as BIOBank Synergy® to address a broad range of surgical needs.

26 September 2025

Plan-Les-Ouates & Zurich (CH) – Antwerp (BE)

Spineart (www.spineart.com), a global medtech innovator in advanced spine surgery solutions, today announces a CHF 25 million capital increase backed by its long-standing investors Gimv and EGS Beteiligungen (EGSB). This new funding will fuel Spineart’s next phase of profitable growth, enabling the company to advance its innovation pipeline and strengthen its global footprint in delivering better outcomes for spine surgery patients.

Spineart’s profitable growth strategy is anchored in a comprehensive portfolio of cutting-edge technologies designed to make spine surgery safer, more efficient and more effective. With a strong focus on clinical outcomes, the company is expanding across Europe and the United States with ongoing regulatory submissions to the U.S. FDA for its BAGUERA® C cervical disc prosthesis. Strategic partnerships and investments in digital navigation and robotics are also enhancing Spineart’s innovation capabilities, adding a transformative dimension to its future growth.

Spineart currently employs over 360 professionals worldwide and is projected to reach revenues of approximately EUR 140 million in 2025, reflecting five consecutive years of growth at an average annual rate of +16%. With a recently opened modern production facility in Reignier, France, the company is well-positioned to meet the rising global demand for its advanced spine surgery solutions.

“This investment represents a major milestone in Spineart’s profitable growth journey,” said Jerome Trividic, CEO of Spineart. “Over the past years, we’ve made targeted strategic investments in product innovation, robotics, regulatory expansion in Europe and the United States and manufacturing, that are now coming to fruition. With the continued support of Gimv and EGSB, we are well-positioned to scale globally, deliver innovative, differentiated technologies and reinforce our commitment to surgical excellence and improved patient outcomes.”

“Our sustained commitment to Spineart reflects our strong belief in the company’s innovation capabilities in the field of spine surgery and its international growth potential,” said Bart Diels and Gautier Lefebvre, respectively Managing Partner and Partner Healthcare of Gimv. “This investment fits perfectly with the ambition of our Healthcare platform to support pioneering companies shaping the future of healthcare and demonstrates our ability to successfully do it on the long run. This additional investment underlines Gimv’s accelerated growth ambitions. The total cumulative investment in the company makes it one of Gimv’s five largest investments.”

“As an investor in Spineart since 2020, we are very pleased with its strong development and remain fully committed to supporting this outstanding company,” said Dominik Sauter, former Managing Director and current Senior Advisor, and Christian Pfab, Member of the Executive Committee of EGSB. “Our additional investment underscores our dedication to fostering entrepreneurship and helping innovative businesses scale and thrive internationally.”

Spineart announces the full-market launch of its SCARLET® AC-Ti secured anterior cervical cage in the United States.

Following 510(k) clearance in May 2024, SCARLET® AC-Ti has been extensively evaluated by clinical experts and this launch signifies the Company’s continued commitment to US product expansion.

After implanting more than 50 SCARLET® AC-Ti, Zakhria Belasher, MD* from Insight Surgical Hospital shared, “With SCARLET® AC-Ti, I have observed consistent performance, reliable standalone stability—with no instances of postoperative dysphagia. Its intuitive design, porous titanium structure, and optimized screw angulation promotes early fusion while enhancing patient recovery and surgical efficiency, making it a seamless and trusted component of my anterior cervical fusion practice!”

Alessia Erlingher, Chief Commercial Officer at Spineart said, «With SCARLET® AC-Ti, we’re bringing an exciting new advancement to the ACDF segment in the US, reinforcing our ongoing commitment to innovation. Following the highly promising results from the initial release phase, we are thrilled to now make this latest technology available to more surgeons.”

SCARLET® AC-Ti builds on a decade of experience with the SCARLET® system and utilizes our Ti-LIFE technology, a proprietary additive manufacturing process, providing a porous structure that closely mimics the trabecular bone structure. Our secured anterior cervical cage is known for its redefined anatomical shape, integrated screw guides and anti-backout mechanism.

To learn more about SCARLET® AC-Ti, contact your local sales representative or complete the form: https://www.spineart.com/us/contact/

*Dr. Belasher is a paid consultant of Spineart. His statements represent his own opinions based on personal experience and are not necessarily those of Spineart. Individual results may vary.